Alnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.
Follow ALNY
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
774.71 | 537.99 | 313.75 | 43.57 |
+8 more TTM periods Free account |
Depreciation & Amortization |
54.76 | 54.81 | 55.66 | 56.32 | |
Non Cash Items (Other) |
660.24 | 645.57 | 599.46 | 645.90 | |
Accounts Receivable Change |
(357.64) | (462.95) | (359.96) | (603.72) | |
Change in inventories |
(11.93) | (1.06) | 8.47 | 23.18 | |
Accounts Payable Change |
(39.84) | 56.77 | 75.07 | 187.81 | |
Change in other assets and liabilities |
(168.49) | (116.22) | (168.36) | (87.20) | |
Operating Cash Flow |
911.81 | 714.90 | 524.08 | 265.86 | |
Capital expenditures |
(91.95) | (71.56) | (58.70) | (44.50) | |
Short Term Investments Change (Net) |
150.21 | 326.00 | 497.18 | 467.35 | |
Long-Term Investments Change (Net) |
44.73 | 44.73 | 0.00 | 0.00 | |
Other investing activities |
(28.17) | — | (2.27) | (6.70) | |
Investing cash flow |
74.94 | 297.02 | 436.33 | 420.59 | |
Repayment/Issuance of Debt (Net) |
— | — | (568.82) | (371.45) | |
Equity Repurchase (Common, Net) |
166.16 | 213.82 | 250.03 | 244.61 | |
Other financial activities |
(56.31) | (62.26) | — | (70.10) | |
Financing cash flow |
(377.00) | (335.56) | (305.19) | (319.51) | |
Exchange Rate Adjustment |
(16.14) | 13.81 | 34.94 | 23.37 | |
Change in Cash |
593.62 | 690.17 | 690.16 | 390.30 | |
Beginning Cash |
1,658.81 | 1,658.81 | 968.65 | 968.65 | |
Ending Cash |
2,252.42 | 2,348.98 | 1,658.81 | 1,358.96 | |
Stock Based Compensation |
336.62 | 361.68 | 348.24 | 368.25 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(577.90) | (523.47) | (444.78) | (479.92) | |
Investments Change (Net) |
194.94 | 370.73 | 497.18 | 467.35 | |
Issuance/Purchase of Shares |
166.16 | 213.82 | 250.03 | 244.61 |